A Study of Intratumoral IMO-2125 in Patients With Refractory Solid Tumors

Melanoma Clinical Trial

— ILLUMINATE-101  

Official title:

A Phase 1b Study of Intratumoral IMO-2125 in Patients With Refractory Solid Tumors (ILLUMINATE-101)

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT03052205
• Other study ID #: 2125-RST-101
• Status: Completed
• Phase: Phase 1
• Start date: June 9, 2017
• Est. completion date: October 4, 2019

Study information

• Verified date: February 2020
• Source: Idera Pharmaceuticals, Inc.
• Contact: n/a
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

This is a Phase 1b study that incorporates dose expansion cohorts to further evaluate promising clinical or biological activity.

Recruitment information / eligibility

• Status: Completed
• Enrollment: 54
• Est. completion date: October 4, 2019
• Est. primary completion date: July 24, 2019
• Accepts healthy volunteers: No
• Gender: All
• Age group: 18 Years and older

Eligibility

Inclusion Criteria:

1. Patients must have histologically or cytologically confirmed diagnosis of cancer not amenable to curative therapy.

2. Patients who have a diagnosis for which a PD-(L)-1 inhibitor has been approved must have previously received treatment with one of these therapies.

a. Melanoma Dose Expansion: Patients must have histologically confirmed metastatic melanoma (ocular melanoma not included) which has progressed on or after treatment with a PD-(L)1 inhibitor.

3. a) Dose Evaluation Portion: Patients should have at least one lesion accessible for intratumoral injection and biopsy.

b) Melanoma Expansion Cohort: Patients must have at least one target lesion by Response Evaluation Criteria for Solid Tumors (RECIST v1.1), with at least one lesion accessible for intratumoral injection. Tumor biopsies are not required in the expansion cohort.

4. Patients must be 18 years of age or older.

5. Patients must have Eastern Cooperative Oncology Group (ECOG) Performance Status =2.

6. Patients must meet the following laboratory criteria:

1. Absolute neutrophil count ANC =1.5 x 109/L (=1500/mm3)

2. Platelet count =75 x 109/L (=75,000/mm3)

3. Hemoglobin =8.0 g/dL (=4.96 mmol/L)

4. Serum creatinine =1.5 x ULN or calculated 24-hour creatinine clearance =60 mL/minute

5. Aspartate aminotransferase (AST) =2.5 x ULN; ALT =2.5 x ULN or AST/ALT <5 x ULN if liver involvement

6. Total bilirubin =1.5 x ULN, except in patients with Gilbert's Syndrome who must have a total bilirubin <3 mg/dL (51.3 µmol/L)

7. Women of childbearing potential and men must agree to use effective contraceptive methods from Screening throughout the study treatment period and until at least 4 weeks after the last dose of study drug.

8. Patients must be willing and able to provide signed informed consent and comply with the study protocol.

Exclusion Criteria:

1. Patients who have received prior therapy with a TLR agonist Patients who have received experimental vaccines or immune therapies other than PD-(L)1 or cytotoxic T-lymphocyte-associated protein 4 (CTLA-4) inhibitors (e.g., Imlygic®) should be discussed with the Medical Monitor to confirm eligibility.

Note: (prior treatment with a topical TLR agonist (e.g. imiquimod) is permitted).

2. Patients who have received treatment with IFN-a within the previous 6 months prior to enrollment.

3. Patients with known hypersensitivity to any oligodeoxynucleotide that cannot be adequately managed with appropriate prophylaxis; e.g. steroids.

4. Patients with active autoimmune disease requiring disease-modifying therapy.

5. Patients requiring concurrent systemic steroid therapy higher than physiologic dosage (>10mg/day of prednisone or equivalent).

6. Patients with another primary malignancy that has not been in remission for at least 3 years, unless approved by the Idera Medical Monitor. The following are exempt from the 3-year limit: non-melanoma skin cancer, curatively treated localized prostate cancer with non-detectable prostate-specific antigen, cervical carcinoma in situ on biopsy or a squamous intraepithelial lesion on Papanicolaou (Pap) smear, and thyroid cancer (except anaplastic).

7. Patients with active infections requiring systemic treatment.

8. Patients who are known to be hepatitis B surface antigen positive.

9. Patients with a known diagnosis of human immunodeficiency virus (HIV) infection.

10. Women who are pregnant or breastfeeding.

11. Patients with known central nervous system, meningeal, or epidural disease. Patients with stable brain metastases following definitive local treatment are eligible if steroid requirement is <10 mg/day of prednisone (or equivalent).

12. Patients with impaired cardiac function or clinically significant cardiac disease:

1. New York Heart Association Class III or IV cardiac disease, including preexisting clinically significant ventricular arrhythmia, congestive heart failure, or cardiomyopathy

2. Unstable angina pectoris =6 months prior to study participation

3. Acute myocardial infarction =6 months prior to study participation

4. Other clinically significant heart disease (i.e., Grade =3 hypertension, history of labile hypertension, or poor compliance with an anti-hypertensive regimen)

13. Have not recovered (to baseline or Grade =1) from toxicity associated with prior treatment.

Related Conditions & MeSH terms

• Melanoma
• Refractory Solid Tumors

Intervention

Drug:
• IMO-2125
IMO-2125 will be administered by intratumoral injection on Days 1, 8, and 15 of Cycle 1 and on Day 1 of each subsequent cycle.

Locations

Country	Name	City	State
Israel	Rambam Medical Center	Haifa
Israel	Hadassah Medical Center	Jerusalem
Israel	Rabin Medical Center Beilinson Campus	Petah tikva
Israel	The Ella Lemelbaum Institute for Immuno-Oncology	Ramat Gan
United States	Roswell Park Cancer Institute	Buffalo	New York
United States	The Cleveland Clinic Foundation	Cleveland	Ohio
United States	St. Luke's Hospital	Easton	Pennsylvania
United States	MD Anderson Cancer Center	Houston	Texas
United States	UPMC Hillman Cancer Center	Pittsburgh	Pennsylvania
United States	University of California San Francisco (UCSF)	San Francisco	California
United States	Scottsdale Healthcare Hospitals DBA Honor Health	Scottsdale	Arizona
United States	The University of Arizona Cancer Center	Tucson	Arizona

Sponsors (1)

Lead Sponsor	Collaborator
Idera Pharmaceuticals, Inc.

Countries where clinical trial is conducted

United States,  Israel, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Dose Evaluation Cohorts, non-Melanoma Dose Evaluation Cohorts: Number of patients with treatment-related adverse events as assessed by CTCAE to determine the recommended Phase 2 dose (RP2D).		51 weeks of treatment
Primary	Dose Evaluation Cohorts, non-Melanoma Dose Evaluation Cohorts: Objective response rate		Assessed every 6 weeks for duration of study participation, which is estimated to be 51 weeks
Primary	Melanoma Expansion Cohort: Objective response rate		Assessed every 9 weeks for duration of study participation, which is estimated to be 51 weeks
Primary	Melanoma Expansion Cohort: Number of patients with treatment-related adverse events as assessed by CTCAE		51 weeks of treatment